Telitacicept 160mg ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
66IgA腎症1

66. IgA腎症


臨床試験数 : 275 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04905212
(ClinicalTrials.gov)
November 4, 202121/5/2021A Study of Telitacicept for Injection (RC18) in Subjects With IgA NephropathyA Phase 2, Randomized, Double-Blind, Multicenter Study of Telitacicept for Injection (RC18) With an Optional Open Label Extension in Subjects With IgA NephropathyIgA NephropathyDrug: Telitacicept 160mg;Drug: Telitacicept 240mg;Drug: PlaceboRemeGen Co., Ltd.NULLRecruiting18 YearsN/AAll30Phase 2United States